Skip to main content

Table 2 DNAm estimated cumulative lead exposure and PD risk

From: DNA methylation biomarker for cumulative lead exposure is associated with Parkinson’s disease

   SGPD (n = 1889) PEG (n = 807) Meta-analysis Test of study heterogeneity
   OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value Q p-value
MODEL 1 DNAm Tibia-lead 2.06 (1.66, 2.56) 5.4E−11 1.60 (1.20, 2.15) 0.001 1.89 (1.59, 2.24) 8.09E−13 1.32 0.25
MODEL 2 1.54 (1.22, 1.95) 2.8E−04 1.48 (1.03, 2.13) 0.019 1.52 (1.25, 1.86) 2.84E−05 1.87 0.17
MODEL 1 DNAm Patella-lead 0.59 (0.45, 0.78) 1.6E−04 1.19 (0.82, 1.73) 0.356 No replication (study heterogeneity) 8.83 0.003
MODEL 2 0.70 (0.53, 0.93) 0.015 1.18 (0.80, 1.75) 0.417 7.53 0.006
  1. Model 1: adjusts for age (DNAmAge in SGPD), sex, ancestry (PEG only)
  2. Model 2: adjusts for age (DNAmAge in SGPD), sex, ancestry (PEG only), smoker (PEG only), blood cell composition, and meanMethBySample